BioLineRx Begins Trial On BL-8040/ Keytruda Combination
Zacks Investment Research | Sep 20, 2016 11:17PM ET
BioLineRx, Ltd. (NASDAQ:BLRX) announced the initiation of a phase IIa trial on its lead oncology candidate, BL-8040, in combination with Merck & Co., Inc.’s (NYSE:MRK) lung cancer drug Keytruda (pembrolizumab), for the treatment of patients with metastatic pancreatic cancer.
BL-8040 is a short peptide that functions as a high-affinity antagonist for CXCR4, a chemokine receptor directly involved in tumor progression, angiogenesis, metastasis and cell survival.
Phase IIa COMBAT is an open-label, multicenter, single-arm trial designed to evaluate the safety and efficacy of the combination of BL-8040 and Keytruda in up to 30 patients suffering from metastatic pancreatic adenocarcinoma, the most common type of pancreatic cancer.
The COMBAT study is also designed to assess the ability of the candidate in improving the infiltration of T cells into the tumor and their reactivity in patients suffering from pancreatic cancer.
The COMBAT study will be conducted in the U.S., Israel and other countries.
According to the company’s press release, in the U.S., 50,000 patients were diagnosed with pancreatic cancer in 2015, among which pancreatic adenocarcinoma accounted for about 85%. This demonstrates the huge market potential for this combination therapy.
Earlier this month, BioLineRx inked a collaboration agreement with a global pharma company — Genentech, a subsidiary of Roche Holding (SIX:ROG) AG (OTC:RHHBY) — for conducting several phase Ib studies on BL-8040, in combination with atezolizumab, in the treatment of multiple cancer indications.
BIOLINE RX LTD Price
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.